---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059424"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:44:52.444579+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data

## Summary
- Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.
- Cash $191.3M at March 31, 2023, down from $194.4M; cash runway into Q1 2025.
- HBV002 trial met endpoints; meaningful HBsAg reductions; final data to be presented at EASL June 21-24.
- APOLLO HPV trial showed favorable tolerability and T-cell responses; final 12-month data expected Q2 2024.
- Appointed Nadège Pelletier as CSO; COO Chris Ellis to retire Oct 31, 2023.

## SEC filing metadata
- accession: 0001104659-23-059424
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/0001104659-23-059424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/tm2315505d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059424
- JSON: https://secwatch.observer/filing/0001104659-23-059424.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059424.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported financial results for the first quarter of 2023.
  - Period: the first quarter of 2023
  - Result: reported results
  source text: today announced its financial results for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/0001104659-23-059424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.